The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 ID6143. We have recently invited stakeholders to respond to a written consultation on the draft scope for this evaluation.
The company that market baricitinib have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience.
As this evaluation has been referred to NICE, we will continue to monitor any development and will update interested parties if the situation changes.
If you have any comments or concerns, please contact the project manager for this proposed appraisal Emily Richards on emily.richards@nice.org.uk